Alzheimer's Aducanumab Redosing Study Underway

(MedPage Today) -- While the Alzheimer's field waits for the FDA's decision on the investigational treatment aducanumab, drug developer Biogen has provided details and endpoints of EMBARK, the drug's ongoing phase IIIb redosing study.
Aducanumab...